Valneva and pfizer complete recruitment for phase 2 trial of lyme disease vaccine candidate

Saint- herblain ( france) and new york, ny , july 19 , 2021 – valneva se (nasdaq: valn; euronext paris: vla), a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, and pfizer inc. (nyse: pfe), today announced that they have completed recruitment for the phase 2 trial, vla15-221, of lyme disease vaccine candidate, vla15. the trial builds on previous positive phase 2 trials and includes both adult and pediatric participants with the aim to support acceleration of the vaccine candidate's pediatric program.
VALN Ratings Summary
VALN Quant Ranking